(Press-News.org) BOTHELL, WA, Feb. 8, 2024 — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis (ALS). The original research article, “ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS,” authored by Berthiaume, A., and Reda, S., et al., was published in the peer-reviewed journal, Frontiers in Neuroscience. ATH-1105 is a next-generation, orally administered small molecule drug candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.
“These data demonstrate that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS. Through enhancement of the neurotrophic HGF system, ATH-1105 protects spinal motor neurons from ALS-relevant insults in vitro and in animal models of ALS, prevents the progressive decline of motor and nerve function, reduces inflammation, preserves body weight and extends survival. Also, the significant reduction in plasma neurofilament light chain (NfL) levels, an established biomarker of neurodegeneration in ALS, is highly encouraging,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira. “These studies further support the therapeutic potential and continued development of ATH-1105, which is targeted to advance into first-in-human studies this year.”
Key findings highlighted in the publication include:
ATH-1105 enhances neurotrophic HGF system signaling and protects primary neuron cultures from various insults relevant to ALS.
ATH-1105 treatment reduced astrocyte reactivity in spinal motor neuron-astrocyte co-cultures and preserved neuromuscular junction integrity in spinal motor neuron-muscle co-cultures following exposure to toxic levels of glutamate, believed to be a key driver of ALS pathology.
In a TDP-43 mouse model of ALS, ATH-1105 treatment significantly preserved body weight, reduced motor and nerve function decline over time, decreased plasma biomarkers of inflammation and neurodegeneration, prevented axonal degeneration and TDP-43 pathology in peripheral nerves, and ultimately extended survival.
“There is an urgent need for new ALS treatment options, particularly those aimed at slowing or stopping neurodegeneration,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. “The results reported in this peer-reviewed publication suggest that ATH-1105 demonstrated consistent translation of neuroprotective and anti-inflammatory effects from in vitro to in vivo models, which led to improved motor function and survival in an ALS animal model. These findings further support our plans to progress ATH-1105 into first-in-human studies in the first half of 2024.”
The article is available on the Frontiers in Neuroscience website and from the Scientific Publications & Presentations page of the company’s website at www.athira.com.
About ATH-1105
ATH-1105 is an orally administered small molecule designed to positively modulate the neurotrophic hepatocyte growth factor (HGF) system, which plays a critical role in nervous system maintenance and repair, including stimulation of cell survival, increase in neuronal outgrowth and modulation of neuronal network repair. In preclinical models of amyotrophic lateral sclerosis (ALS), ATH-1105 has been shown to significantly increase survival, enhance motor and nerve function, reduce peripheral nerve demyelination and axon degeneration, and improve neurodegeneration and inflammation.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton (ATH-1017), which is being evaluated for the potential treatment of mild-to-moderate Alzheimer’s disease in the Phase 2/3 LIFT-AD trial that is targeted to report topline data in the second half of 2024. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn, X (formerly known as Twitter) and Instagram.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases; future development plans; the anticipated reporting of data; expectations regarding the potential efficacy and commercial potential of Athira’s product candidates; and Athira’s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “on track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,” “continue,” “suggest,” “potential,” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira’s product candidates; development of product candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's product candidates with other treatments; Athira’s assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira’s clinical development plans as a result of pandemics or health epidemics, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira’s filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.
END
Athira Pharma announces publication in Frontiers in Neuroscience highlighting therapeutic potential of ATH-1105 in amyotrophic lateral sclerosis (ALS)
Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS
2024-02-08
ELSE PRESS RELEASES FROM THIS DATE:
Sex hormones help gonorrhea fight off antimicrobials and antibiotics
2024-02-08
DURHAM, N.C. – You know that package warning that oral birth control won’t prevent STIs? Well in the case of gonorrhea, the sexually transmitted bacterium that causes the disease can use those hormones to help it resist antibiotic attacks.
Like many bacteria, this bug, Neisseria gonorrhoeae, is equipped with pumps to push the killing chemicals out of its cells. But what’s unique, according to a Duke and Emory study online this week in Nature Communications, is that the hormones of the human urogenital tract actually allow gonorrhea to make and use more of these pumps to fight intrinsic ...
45 finalists named for the 2024 Hertz Fellowships
2024-02-08
The Fannie and John Hertz Foundation today announced 45 finalists for the 2024 Hertz Fellowships in applied science, mathematics and engineering.
Selected from more than 860 applicants and representing 21 universities, the finalists advance to a culminating round of interviews for one of the most competitive and coveted doctoral fellowships in the nation. The 2024 class of Hertz Fellows will be announced in May.
Since 1963, the Hertz Foundation has granted fellowships empowering the nation’s most promising young ...
How one type of lung cancer can transform into another
2024-02-08
Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment. Researchers at Weill Cornell Medicine have developed a mouse model that illuminates this problematic process, known as histological transformation. The findings advance the understanding of how mutated genes can trigger cancer evolution and suggest targets for more effective treatments.
The researchers, whose results were published ...
Results from South Pole Telescope’s new camera emerge
2024-02-08
Argonne is part of a multi-institutional effort to survey the sky for clues about the origins and nature of our universe.
For more than five years, scientists at the South Pole Telescope in Antarctica have been observing the sky with an upgraded camera. The extended gaze toward the cosmos is picking up remnant light from the universe’s early formation. Now researchers have analyzed an initial batch of data, publishing details in the journal Physical Review D. The results from this limited dataset hint at even more powerful future insights about the nature of our universe.
The telescope at the Amundsen-Scott South Pole Station, which is operated by the National ...
Rosenthal Department of Management established at McCombs School of Business
2024-02-08
AUSTIN, Texas — The Management Department in the McCombs School of Business at The University of Texas at Austin has long been recognized as a powerhouse for research excellence and teaching innovation. Now, it holds a new distinction. It is the first academic department in the business school to be named as the result of a generous gift.
The newly named Rozanne and Billy Rosenthal Department of Management has been made possible by a $25 million gift from two married Longhorns, Rozanne Rosenthal, B.S. ’74, and Billy Rosenthal, BBA ’72. ...
Professor of Finance named ECGI Fellow
2024-02-08
AUSTIN, Texas -- In recognition of her research and scholarship, Laura Starks, a professor of finance at The University of Texas at Austin, was recently named a fellow of the European Corporate Governance Institute (ECGI). She is among eight new fellows selected from academia in Europe and the United States. ECGI, founded in 2002, is an international scientific nonprofit association that serves as a forum on corporate governance among academics, legislators, and practitioners.
Starks is the George Kozmetsky Centennial University Distinguished Chair in the McCombs School of ...
NJIT researchers unveil method to detect 'forever chemicals' in under 3 minutes
2024-02-08
PFAS have earned the name “forever chemicals” with good reason — the man-made compounds, which can take thousands of years to degrade and are found in everything from grease-resistant food packaging to water-repellent clothing, have made their way into nearly half the U.S. tap water supply.
Now, in a study featured in Elsevier’s Journal of Hazardous Materials, New Jersey Institute of Technology chemists have demonstrated a new lab-based method to detect traces of PFAS from food packaging material, water and soil samples in just three minutes or less.
Researchers say their approach could ...
Exploring new futures in space: a revolutionary integration of neuroscience, quantum physics, and space exploration
2024-02-08
February 8, 2024, Mountain View, CA — The SETI Institute, leading humanity's quest to understand the origins and prevalence of life and intelligence in the universe and share that knowledge with the world, is pioneering innovative approaches to understanding our place in the cosmos. The SETI Institute is proud to support a groundbreaking project from London-based filmmaker and SETI Institute Designer of Experiences Dr. Nelly Ben Hayoun-Stépanian that combines insights from intergenerational trauma, neuroscience, quantum physics, and ...
Technique could improve the sensitivity of quantum sensing devices
2024-02-08
In quantum sensing, atomic-scale quantum systems are used to measure electromagnetic fields, as well as properties like rotation, acceleration, and distance, far more precisely than classical sensors can. The technology could enable devices that image the brain with unprecedented detail, for example, or air traffic control systems with precise positioning accuracy.
As many real-world quantum sensing devices are emerging, one promising direction is the use of microscopic defects inside diamonds to create “qubits” that can be used for quantum sensing. Qubits are the building blocks of quantum ...
New process allows full recovery of starting materials from tough polymer composites
2024-02-08
In a win for chemistry, inventors at the Department of Energy’s Oak Ridge National Laboratory have designed a closed-loop path for synthesizing an exceptionally tough carbon-fiber-reinforced polymer, or CFRP, and later recovering all of its starting materials.
A lightweight, strong and tough composite material, CFRP is useful for reducing weight and increasing fuel efficiency of automobiles, airplanes and spacecraft. However, conventional CFRPs are difficult to recycle. Most have been single-use materials, so their carbon footprint is significant. By contrast, ORNL’s closed-loop ...
LAST 30 PRESS RELEASES:
Insulin resistance is linked to over 30 diseases – and to early death in women, study of people in the UK finds
Innovative semaglutide hydrogel could reduce diabetes shots to once a month
Weight loss could reduce the risk of severe infections in people with diabetes, UK research suggests
Long-term exposure to air pollution and a lack of green space increases the risk of hospitalization for respiratory conditions
Better cardiovascular health in early pregnancy may offset high genetic risk
Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data releases at IASLC 2024 World Conference on Lung Cancer
Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer
IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer biomarker testing
Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors
Just how dangerous is Great Salt Lake dust? New research looks for clues
Maroulas appointed Associate Vice Chancellor, Director of AI Tennessee
New chickadee research finds cognitive skills impact lifespan
Cognitive behavioral therapy enhances brain circuits to relieve depression
Terasaki Institute awarded $2.3 Million grant from NIH for organ transplantation research using organs-on-a-chip technology
Atoms on the edge
Postdoc takes multipronged approach to muon detection
Mathematical proof: Five satellites needed for precise navigation
Scalable, multi-functional device lays groundwork for advanced quantum applications
Falling for financial scams? It may signal early Alzheimer’s disease
Integrating MRI and OCT for new insights into brain microstructure
Designing a normative neuroimaging library to support diagnosis of traumatic brain injury
Department of Energy announces $68 million in funding for artificial intelligence for scientific research
DOE, ORNL announce opportunity to define future of high-performance computing
Molecular simulations, supercomputing lead to energy-saving biomaterials breakthrough
Low-impact yoga and exercise found to help older women manage urinary incontinence
Genetic studies reveal new insights into cognitive impairment in schizophrenia
Researcher develops technology to provide cleaner energy and cleaner water
Expect the unexpected: nanoscale silver unveils intrinsic self-healing abilities
nTIDE September 2024 Jobs Report: Gains in employment for people with disabilities appear to level off after reducing gaps with non-disabled workers
Wiley enhances NMR Spectral Library Collection with extensive new databases
[Press-News.org] Athira Pharma announces publication in Frontiers in Neuroscience highlighting therapeutic potential of ATH-1105 in amyotrophic lateral sclerosis (ALS)Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS